Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Technical analysis for shorts & longs -- Ignore unavailable to you. Want to Upgrade?

To: Johnny Canuck who wrote (27030)	6/15/2000 9:48:00 PM
From: Johnny Canuck	Read Replies (1) \| Respond to of 68226

Power-One (PWER) 79 5/8 +3/8: Needham & Co reiterates STRONG BUY rating and price target of $102; cites PWER's increased business from Qwest, Nokia, Motorola, and Lucent; says PWER is only independent pure play in exploding telecom power plant industry. Brooktrout Tech (BRKT) 21 -3/8: George K. Baum reiterates BUY rating with price target of $33-38; believes BRKT's quarter is on track, and "New Network" opportunities should contribute nicely to quarter. Visual Networks (VNWK) 32 3/4 -3 1/2: Mrgn Stnly Dn Wttr reiterates STRONG BUY rating and price target of $75. Firm attributes recent weakness (down 35%) to concerns regarding back-end loading in C2Q00. Believe visibility is unchanged from C1Q00 and that shares reflect a miss in June where downside is limited. Nokia (NOK) 57 7/16 -1 7/16: Bear Stearns reiterates BUY after company presents at firm's conference yesterday. Cites strength of business and expects company to meet or beat Q2 consensus estimates ($0.19). Gilead Sciences (GILD) 60 3/16 -2 1/2: Banc of America Sec initiates coverage with a BUY rating and price target of $84; views GILD as fully integrated, global biopharmaceutical company trading at significant discount to group; believe stock remains undervalued due to lack of news flow expected during next six months, misperceptions regarding two pipeline products (tenofovir and adefovir), and because company is not profitable. Immunex Corp (IMNX) 35 15/16 +1 35/64: Banc of America Sec initiates coverage with a STRONG BUY rating and price target of $51; believe IMNX is premiere biotechnology company with one of most promising product pipelines in the industry; projects sales of Enbrel for rheumatoid arthritis of $640 mln in 2000. IDEC Pharm (IDPH) 97 1/16 -1/2: Banc of America Sec initiates coverage with a STRONG BUY rating and price target of $139. Analyst believes that investor misperceptions have caused the stock to become undervalued, and expect resolution of each to push the stock higher. Although Rituxan sales growth has appeared to slow during the last three quarters, inventory issues have clouded true underlying demand. The recent negative data for IDEC-131 in lupus does NOT spell disaster for the product. Expect clarification for future development to occur on the second quarter conference call with two new autoimmune disease indications to be announced and initiated by the end of 2000. QUALCOMM (QCOM) 70 1/2: Chase H&Q reiterates an MARKET PERFORM rating, but initiates a sub-market $50 target, citing Korea, China, and Globalstar (GSTRF) concerns. As reported yesterday, Bear Stearns cut its numbers on QCOM due to Korean weakness, uncertainty over CDMA deployment in China, and exposure to GSTRF; reduces FY00 by $0.03 and FY01 by $0.10.